Details of the Drug

General Information of Drug (ID: DMFQEA6)

Drug Name
Pembrolizumab
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1], [2]
Breast cancer 2C60-2C65 Phase 3 [3]
Colorectal cancer 2B91.Z Phase 3 [3]
Esophageal cancer 2B70 Phase 3 [3]
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Renal cell carcinoma 2C90 Phase 3 [3]
Small-cell lung cancer 2C25.Y Phase 3 [3]
Cutaneous squamous cell carcinoma 2C30 Phase 2 [4]
Ovarian cancer 2C73 Phase 2 [3]
Prostate cancer 2C82.0 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Primary mediastinal B-cell lymphoma 2A81 Application submitted [3]
Drug Type
Monoclonal antibody
Sequence
>heavy chain
QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNF
NEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGK
>light chain
EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLES
GVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Clearance
The clearance of drug is 195 mL/day [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 22 days [5]
Metabolism
The drug is metabolized via the general protein degradation [6]
Vd
The volume of distribution (Vd) of drug is 6 L [5]
Cross-matching ID
DrugBank ID
DB09037
TTD ID
D08ANZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pembrolizumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Deflazacort DMV0RNS Moderate Additive immunosuppressive effects by the combination of Pembrolizumab and Deflazacort. Muscular dystrophy [8C70] [13]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 FDA Approved Drug Products: Keytruda (pembrolizumab) solution for intravenous injection
6 Criddle DN, Gillies S, Baumgartner-Wilson HK, Jaffar M, Chinje EC, Passmore S, Chvanov M, Barrow S, Gerasimenko OV, Tepikin AV, Sutton R, Petersen OH: Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem. 2006 Dec 29;281(52):40485-92. doi: 10.1074/jbc.M607704200. Epub 2006 Nov 6.
7 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8 Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
9 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
10 Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
11 Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".